cinaciguat

Known as: 4-(((4-Carboxybutyl)(2-(2-((4-(2-Phenylethyl)Phenyl)Methoxy)Phenyl)Ethyl)Amino)Methyl)Benzoic Acid 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
0246820082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
AIMS Cinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator. This study evaluated the haemodynamic effect and… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2012
2012
Cinaciguat (BAY 58-2667) is a novel nitric oxide (NO)-independent activator of soluble guanylate cyclase (sGC), which induces… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
AIMS Cinaciguat (BAY 58-2667) is a soluble guanylate cyclase (sGC) activator that, in a previous study among patients with acute… (More)
Is this relevant?
2012
2012
Nitric oxide (NO) signaling mediates many important physiological processes through the receptor soluble guanylate cyclase (sGC… (More)
Is this relevant?
2011
2011
OBJECTIVE Activation of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway can… (More)
Is this relevant?
2011
2011
Although inhaled NO (iNO) therapy is often effective in treating infants with persistent pulmonary hypertension of the newborn… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2010
2010
The nitric oxide (NO)/soluble guanylate cyclase (sGC)/cyclic guanosine-3',5'-monophosphate (cGMP) pathway plays an important role… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase activators in clinical development… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2009
2009
Impaired nitric oxide-cGMP signaling contributes to severe pulmonary hypertension after birth, which may in part be due to… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2008
2008
Preclinical data indicate that the nitric oxide-independent soluble guanylate cyclase activator cinaciguat (BAY 58-2667), which… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?